Biotech & MedTech News
-
DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange
November 12, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A)…
-
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients…
-
DIAGNOS Announces Closing of Private Placement
October 25, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
October 24, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
DIAGNOS Announces the Engagement of Market Maker Consultant
October 17, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Voyageur Announces Proposed Private Placement
October 17, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Corporation”), is pleased to…
-
Coeptis Therapeutics’ Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy
October 15, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
DIAGNOS Announces Grant of Stock Options
October 03, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Voting Results of Meeting of Shareholders
September 26, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Voyageur Pharmaceuticals Grants Stock Options
September 25, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”) announces that…
